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1. Introduction 
Heart transplantation is a life-saving procedure for patients with end-stage  
cardiac dysfunction. Currently one-year graft survival ranges between 77-88%,  
three-year survival between 77-79% and five-year survival between 67-73% 
(http://www.americanheart.org/presenter.jhtml?identifier=4588). Despite these encouraging 
results, primary graft failure accounts for about 23% of deaths in the first 90 days post 
transplantation. Pretransplant variables associated with primary graft failure include: 
ischemia time, donor gender, donor age, multiorgan donation, center volume, 
extracorporeal membrane oxygenation, mechanical circulatory support, etiology of heart 
failure, and reoperative heart transplantation (Russo et al., 2010). To target rejection of 
allografts, a variety of immunosuppressive protocols are used solely in the recipient who is 
the main focus of the therapy (The International Society of Heart and Lung Transplantation 
Guidelines for the Care of Heart Transplant Recipients Task Force 2: Immunosuppression 
and Rejection (Nov. 8, 2010)). Typically, neither donor nor grafts are specifically treated 
before or during organ harvesting except for the maintenance of circulatory and respiratory 
functions of the donor and irrigation of grafts with preservation solutions. 
2. Graft rejection 
A T-cell driven process mediated by the adaptive immune system is our classic 
understanding of graft rejection. Allogeneic MHC molecules on graft tissue are recognized 
by the recipient’s immune system by two pathways, the direct and the indirect pathway. 
Alloreactive T-cells in the direct pathway recognize donor MHC molecules on antigen-
presenting cells (APCs) which pass through the transplanted tissues (Larsen et al., 1990). 
APCs in the indirect pathway process antigens which are derived from donor MHC 
molecules and present them to alloreactive T-cells (Game & Lechler, 2002). Their activation 
is further fuelled by co-stimulatory molecules such as the CD40-CD40 ligand (CD154) 
receptor-ligand pathway (Cho et al., 2000). This co-stimulation, in case of graft endothelial 
cells, not only reinforces T-cell activity but enhances the later recruitment of effector 






exaggerated, causes damage to the capillary microcirculation, organ dysfunction and 
ultimately graft loss (Cho et al., 2000; Rocha et al., 2003).  
Although T-cells are believed to play a critical role in acute rejection, it could be shown that 
expression of pro-inflammatory mediators within the allograft is up-regulated even before 
the T-cell response. This response is mediated by the innate immune system which is 
independent of the adaptive immune reaction (Christopher et al., 2002; He et al., 2002; He et 
al., 2003). By means of RNase protection assay in a mouse heart transplantation model it has 
been shown that one day after transplantation the gene expression profile of the cellular 
infiltrate, namely chemokine receptor expression and the expression of pro-inflammatory 
cytokines, was similar in RAG-deficient mice as compared to immunologically competent 
wild type mice (He et al., 2002). It could therefore be concluded that innate, antigen-
independent pro-inflammatory processes occur shortly after transplantation and are further 
specifically modified by the adaptive immune response (He et al., 2003). 
3. Innate immune system and ischemia reperfusion in organ transplantation 
Multicellular organisms have developed immunological mechanisms to detect and to 
rapidly respond to threats. Such immunological mechanisms are being referred to as innate 
immunity. Unlike the evolutionary younger adaptive immune system, the innate immune 
system performs its control function by using so-called "pattern recognition" receptors 
(PRRs) (Janeway & Medzhitov, 2002). PRRs identify pathogenic molecules, microbial "non-
self" (pathogen-associated molecular patterns [PAMP]) or recipient molecules released from 
damaged or "stressed" tissues ("damaged self" or damage-associated molecular patterns 
[DAMP]) that differ from "self" which are thought to signal through PRRs such as toll-like 
receptor 4 (TLR4) in a manner similar to PAMPs (Mollen et al., 2006).  
Different cell types play a role in the effector response, among others dendritic cells, natural 
killer cells and endothelial cells. They detect PAMPs as exogenous and DAMPs as 
endogenous ligands through toll-like receptors (Land, 2003; Land, 2005; Takeda & Akira, 
2005) (Figure 1). 
Engagement of DAMPs with TLRs leads to activation of transcription factors STAT-1, AP-1, 
NF-B and IRF-3 followed by chemokine (e.g. MCP-1) and pro-inflammatory cytokine 
release, graft damage and ultimately graft loss. 
After recognition of PAMPs the activated TLRs initiate an intracellular signalling cascade 
which leads to activation of transcription factors such as, e.g. activator protein-1 (AP-1), 
nuclear factor-κB (NF-κB) or interferon regulatory factor-3 (IRF-3), expression of pro-
inflammatory genes and, e.g. maturation of dendritic cells (Ishitani et al., 2003; Hemmi & 
Akira, 2005; Kishida et al., 2005; Sato et al., 2005; Shim et al., 2005; Takeda & Akira, 2005). 
Mature dendritic cells interact with naïve T-cells and trigger a T-cell response. They act 
therefore as a link between innate and adaptive immunity.  
The process of organ injury starts even before the recipient’s immune system has the first 
contact with donor cells. Its starts with the oxidative damage to the graft in the brain-dead 
donor and continues after reperfusion (Land, 2005). NADPH oxidase-dependent reactive 
oxygen species (ROS) production is involved in translocation of TLR4 to lipid rafts 
(Nakahira et al., 2006), i.e. micro-domains of the cell membrane, a process that is important 
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Fig. 1. Scheme of the innate immunity effector response after challenge by DAMPs 
(modified after Land 2007 (Land, 2007)). 
in signal transduction (Dykstra et al., 2003; Manes et al., 2003). DAMPs like heat shock 
protein 72 (HSP 72), high mobility group box 1 (HMGB-1) and fragments of hyaluronic acid 
(fHA) are recognised by TLR4 and/or TLR2 (Land, 2007). Activation of these TLRs initiates 
a signal transduction cascade to the nucleus through molecules like myeloid differentiation 
marker 88 (MyD88), TIR-associated protein (TIRAP) und TIR domain-containing adaptor 
inducing IFN-β (TRIF), ultimately leading to activation of the transcription factors AP-1, NF-
kB or IRF-3, up-regulation of pro-inflammatory gene expression and, among others, 
maturation of dendritic cells that all fuel the immunologic reaction against the graft (Land, 
2007).  
In summary, ROS in the brain-dead donor and during reperfusion cause i) initial graft 
damage which activates the innate immune response, ii) activation of signalling pathways 
which further augment this response and iii) boosting of humoral, complement-mediated 
tissue damage (Land, 2007).  
4. Graft rejection and endothelial cells 
In the setting of graft rejection, endothelial cells are the first donor cells which are affected 
by activation of the innate and adaptive immune response of the recipient. Integrity of the 
donor endothelium is of pivotal importance to graft function because injury to the 
endothelium ultimately leads to perfusion failure and graft loss. In addition, the endothelial 
cells themselves activate the innate immune response thereby maintaining a vicious circle 






innate immune response occurs very early at the level of the donor endothelial cells. In this 
context, systemic immunosuppressive therapy has the disadvantage of being initiated in the 
recipient while graft damage is already in transition and furthermore it does not specifically 
target endothelial cell damage. In fact, it may even augment it. Therefore, an adjunct pre-
transplant therapy solely within the graft that addresses the pro-inflammatory effects of the 
innate immune response on the endothelium seems to hold great promise. Moreover, by 
excluding systemic effects, the therapy can be adequately dosed and administered directly 
to the target site because the graft vessels are readily accessible after organ explantation. 
5. Decoy oligodeoxynucleotide technology in organ transplantation 
To specifically address this setting, the decoy oligodeoxynucleotide (ODN) technology may 
provide a specific tool to directly interfere with target gene expression. Decoy (decoy=bait) 
ODNs are short double-stranded DNA molecules with a specific sequence of bases that 
typically matches the consensus DNA recognition motif of the target transcription factor. With 
these nucleic acid-based drugs it is possible to effectively inhibit the expression of genes which 
are controlled by the said transcription factor (Morishita et al., 1995). Most mammalian cells 
are easily transfected with these DNA molecules. In fact, their uptake by most target cells does 
not require any transfection agent or the like, and under physiological conditions is mediated 
by active transport, i.e. a carrier system and/or receptor mediated endocytosis (Figure 2). 
The synthetic, 15 to 25 bp long DNA fragments usually are stabilized by replacing 2 to 3 of 
the terminal phosphodiester bonds between the nucleotides by phosphothio-ester bonds  
 
 
Fig. 2. Decoy ODN mechanism of action. Scheme depicting the mechanism of action of 
decoy ODN-mediated neutralization of the targeted transcription factor (TF). 1 refers to 
cytoplasmic TF sequestration, 2 to nuclear TF sequestration, and 3 to removal of promotor-
bound TF through titration with high-affinity decoy ODNs. 
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that afford remarkable protection against exonucleases so that they remain intact in the target 
cells for some days. As mentioned above, decoy ODNs typically harbour at least one binding 
site for a particular transcription factor or transcription factor family. The length of this 
binding site normally is derived from known DNA binding motifs for the target transcription 
factor in different species and on the basis of their homology (consensus sequence).  
Following their uptake by the respective target cell(s), decoy ODNs bind to their target 
transcription factor with high affinity (comparable to the formation of an antigen-antibody 
complex) thereby preventing it from translocation to the nucleus and/or effectively 
neutralizing its activity therein. 
6. Role of interferon- and signal transducer and activator of transcription-1 
(STAT-1) in transplant rejection 
Acute cellular rejection reduces the short and long-term outcome after transplantation. 
Recipient immune cells are recruited from the circulation into the transplant by presentation 
of antigens to T-helper cells whose activation is further increased by co-stimulatory 
molecules such as the CD40-CD154 receptor-ligand pathway (Cho et al., 2000). As a 
consequence, activated T-helper cells induce the increased expression of adhesion molecules 
on the endothelial cells of the donor organ, which leads to further recruitment of circulating 
monocytes into the graft and ultimately graft failure (Cho et al., 2000).  
An important cytokine that is produced by activated T-helper cells is interferon-γ (IFN-γ). 
Due to activation of the transcription factor signal transducer and activator of transcription-
1 (STAT-1) IFN-γ up-regulates the expression of a number of important genes for graft 
rejection in the endothelial cells of the donor organ such as, e.g. vascular cell adhesion 
molecule-1 (VCAM-1) or CD40 (De Caterina et al., 2001; Wagner et al., 2002). VCAM-1 
expression, for example, fuels leukocyte-endothelial cell interaction which is a hallmark of 
acute vascular rejection (De Caterina et al., 2001; Wagner et al., 2002).  
Signalling of IFN-γ to the nucleus of an endothelial cell starts with its binding to the 
corresponding receptor on the cell surface which then dimerizes (Bach et al., 1997; Boehm et 
al., 1997; Pestka, 1997). As a consequence, the receptor-associated tyrosine kinases JAK1 and 
JAK2, members of the Janus family of kinases (Boehm et al., 1997; Pestka, 1997), translocate 
to the cell membrane. There they phosphorylate the cytoplasmic domain of the IFN-γ 
receptor which is now able to recruit monomeric STAT-1 (Ivashkiv, 1995; Ihle, 1996; Darnell, 
1997). After phosphorylation and dimerization the now active transcription factor 
translocates to the nucleus and stimulates IFN-γ-dependent gene expression by binding to 
the gamma-interferon-activated element (GAS) in the promoter region of its target genes 
(Ivashkiv, 1995; Ihle, 1996; Darnell, 1997). In addition to CD40, the expression of ICAM-1 
(Naik et al., 1997) or that of the inducible isoform of nitric oxide (NO) synthase is also 
controlled by STAT-1 (Ganster et al., 2001). 
IFN-γ as a multifunctional cytokine therefore controls many pro-inflammatory gene 
products whose expression is stimulated through the IFN-γ/STAT-1 pathway (Khabar et al., 
2004; Khabar & Young, 2007; Liu et al., 2008; Karonitsch et al., 2009). In vivo and in vitro 
experiments showed that the up-regulation of both CD40 and VCAM-1 expression by STAT-
1 is effectively reduced using decoy ODNs directed against this transcription factor (Wagner 






The role of CD40-CD154 co-stimulation in transplant rejection still is the subject of intense 
research (Larsen & Pearson, 1997; Cho et al., 2000). Thus it was shown in human biopsies of 
heart transplants that there is a significant correlation between the increased expression of 
CD154 and CD40 on leukocytes and endothelial cells, respectively, and acute rejection (Reul 
et al., 1997). The administration of monoclonal antibodies directed against CD154 prolonged 
renal transplant survival in rats and primates (Gudmundsdottir & Turka, 1999; Hancock, 
1999; Kirk et al., 1999). Furthermore, the application of anti-CD40 antibodies in monkeys led 
to a significant immunosuppressive effect and prolonged graft survival (Imai et al., 2007), so 
that both CD40 and CD154 can be regarded as important target molecules in allograft 
rejection. The clinical development of the corresponding biological (humanized monoclonal 
anti-CD154) antibodies, however was previously thwarted by serious thromboembolic 
complications (Kawai et al., 2000; Koyama et al., 2004), which are suspected to have been 
caused by an interference with the stabilizing effect of soluble CD154 on freshly formed 
thrombi (Andre et al., 2002). In fact, the main source of soluble CD154 are aggregating 
platelets from which the membrane-bound CD154 is shed upon activation (Kaya et al., 2011; 
Pamukcu et al., 2011; Silvain et al., 2011; Yacoub et al., 2010). More recently, however, some 
progress has been made towards the development of monoclonal antibodies with less side 
effects (Hussein et al., 2010). 
CD40 is a cell surface receptor that belongs to the family of tumor necrosis factor receptors. 
It is mainly expressed on B-cells and antigen-presenting cells, but also on other non-immune 
cells such as vascular smooth muscle cells, fibroblasts and endothelial cells (van Kooten & 
Banchereau, 2000; Schonbeck & Libby, 2001). The corresponding ligand, CD154, is a member 
of the TNF family and located on activated T-cells, dendritic cells, mast cells, eosinophils, 
activated platelets and endothelial cells (Cho et al., 2000). CD40 stimulation in endothelial 
cells elicits a marked increase in expression of adhesion molecules and chemokines, which 
in turn facilitate the extravasation of leukocytes and their accumulation in the inflamed 
tissue (Hollenbaugh et al., 1995; Yellin et al., 1995). In addition, endothelial cells, as APCs, 
produce interleukin-12 (IL-12) in response to CD40 stimulation, which may play a crucial 
role in strengthening the T-cell response during graft rejection (Ode-Hakim et al., 1996; 
D'Elios et al., 1997). This IL-12 production is strongly enhanced in the presence of IFN-. 
7. STAT-1 decoy ODN treatment to ameliorate cardiac allograft survival 
Since targeting CD154 therapeutically appears to be wrought with difficulties, CD40 may be 
the more suitable drug target. However, low-molecular-weight CD40 antagonists are not yet 
available and CD40 antibodies, although prolonging graft survival in earlier studies, may 
cause anti-antibody formation and anaphylaxis (Imai et al., 2007). Therefore, an alternative 
approach was sought addressing transcription of the CD40 gene in endothelial cells, and 
this was achieved by employing decoy ODNs directed against the transcription factor 
STAT-1. 
To investigate this novel therapeutic concept in terms of acute and chronic graft rejection, 
STAT-1 decoy ODNs were applied in established models of allogeneic cardiac transplantation 
in rats and mice with or without immunosuppression and in both acute and chronic settings 
(Holschermann et al., 2006; Stadlbauer et al., 2008; Stojanovic et al., 2009). The exclusive 
uptake of the decoy ODNs by the donor coronary endothelium could be confirmed by 
administration of fluorescent dye-labelled nucleic acids. Given the pleiotropic influence of 
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CD154/CD40 expression and of IFN- on pro-inflammatory gene expression and the 
putative beneficial effect of STAT-1 decoy ODNs, the up-regulation of important 
chemokines and adhesion molecules was examined in cardiac allografts following 
periprocedural STAT-1 decoy ODN administration. To this end the expression of, e.g. CD40, 
VCAM-1, E-selectin, MCP-1, ICAM-1 and RANTES (Holschermann et al., 2006; Stojanovic et 
al., 2009) was analyzed. Furthermore, histological parameters of rejection and the profile of 
infiltrating inflammatory cells were monitored (Holschermann et al., 2006; Stadlbauer et al., 
2008; Stojanovic et al., 2009). 
As verified by real time PCR analysis, a single periprocedural application of STAT-1 decoy 
ODNs to the coronary arteries of allogeneic donor heart transplants resulted in a marked 
down-regulation of CD40, VCAM-1, E-selectin, MCP-1, ICAM-1 and RANTES expression in 
allografts but not in isografts 24 hours post transplantation when compared to allograft and 
isograft control hearts (Stojanovic et al., 2009). The corresponding mutant control ODNs 
showed no such effect on expression of these marker genes (Holschermann et al., 2006; 
Stojanovic et al., 2009). 
In fact, expression of these gene products was even lower than in control syngeneic 
transplants. Moreover, in syngenic transplants, irrespective of the chosen treatment regimen, 
no change in the expression of CD40, ICAM-1 or MCP-1 was noted, but an increase in E-
selectin and VCAM-1 expression occurred which probably is the consequence of a moderate 
surgical and ischemia/reperfusion trauma (Stojanovic et al., 2009). The expression of the 
aforementioned pro-inflammatory gene products in the allograft is IFN-γ-dependent and 
controlled by subsequent activation of the transcription factor STAT-1 (De Caterina et al., 2001; 
Burysek et al., 2002; Wagner et al., 2002). In addition, some of these pro-inflammatory gene 
products, e.g. MCP-1, regulate the expression of other pro-inflammatory genes (Saiura et al., 
2004), so that a blockade of IFN--induced MCP-1 expression through STAT-1 decoy ODN 
treatment probably could affect a much larger spectrum of pro-inflammatory gene products. 
Besides MCP-1, which was still up-regulated 9 days after transplantation in the allografts 
compared with syngeneic transplanted hearts, there were no long-term changes in gene 
expression found in the donor hearts, so that the possible inhibitory effect of the STAT-1 
decoy ODN treatment was no longer detectable at this time (Stojanovic et al., 2009).  
When analyzing the profile of infiltrating cells, it was readily apparent that the number of 
infiltrating monocytes/macro-phages and T-cells was significantly reduced 6 days and 9 
days post transplantation as compared to the allogeneic controls (Holschermann et al., 2006; 
Stojanovic et al., 2009). In line with these findings, the vascular and interstitial rejection 
scores were significantly reduced in STAT-1 decoy ODN-treated allografts 9 days post 
transplantation when compared to control allografts (Stojanovic et al., 2009), and 
accordingly a significantly prolonged graft survival was noted after single STAT-1 decoy 
ODN treatment in an allogeneic rat model (Holschermann et al., 2006). 
This approach of specific interference with transcriptional regulation of gene expression by 
using decoy ODNs also holds true when targeting other key molecules involved in CD40 
expression. Thus decoy ODNs directed against the transcription factor AP-1 also inhibited 
endothelial ICAM-1 and VCAM-1 expression and reduced the number of leukocytes, 
namely T-cells, infiltrating the graft blood vessels, and prolonged survival in acute rejection 






Analyzing the course of chronic rejection after single application of either a STAT-1 or 
AP-1 decoy ODN in a rat cardiac transplantation model with immunosuppression 
revealed that after 100 days allografts treated with either decoy ODN showed a 
significantly lesser degree of disease and number of occluded vessels, pointing towards a 
profound inhibition of cardiac allograft vasculopathy (CAV) (Stadlbauer et al., 2008). As 
putative mechanism of action, it was proposed that the AP-1 decoy ODN primarily 
attenuated basal endothelial CD40 expression while the STAT-1 decoy ODN suppressed 
tumour necrosis factor-/IFN--stimulated expression of CD40 in the rat native 
endothelial cells (Stadlbauer et al., 2008). 
In the setting of inflammatory disease in humans another or perhaps alternative mechanism 
of CD40 expression in endothelial cells may also be active. In human cultured endothelial 
cells, combined treatment with IFN- and TNF- induces an IRF-1–dependent de novo 
expression of CD40. Although this effect is indirectly mediated by STAT-1 through 
induction of IRF-1 synthesis, STAT-1 directly induces CD40 expression in these cells when 
exposed to IFN- alone. Thus, it is the cytokine composition under the given pro-
inflammatory conditions that determines which transcription factor is primarily responsible 
for the increase in endothelial CD40 expression (Wagner et al., 2002).  
8. Conclusion 
The primary injury inflicted on the graft before implantation actually takes place currently 
does not receive sufficient attention. The mechanisms of innate immunity, which are 
significantly contributing to primary graft damage, are also not well understood, but at least 
regained scientific interest.  
Herein an attempt was made to highlight some consequences of the inadvertently 
exaggerated activation of the innate immune response in cardiac transplant rejection with 
special emphasis on the role of the donor endothelium and the underlying pro-
inflammatory mechanisms. By blocking the expression of pro-inflammatory gene products 
in these cells beneficial effects on the perfusion of the graft and its histological appearance 
can be achieved. The tested animal experimental models did not comprise a conventional 
immunosuppressive treatment regimen with regard to acute rejection and despite the fully 
allogeneic transplantation setting. There is the distinct possibility therefore that combining 
conventional immunosuppressive therapy with the presented novel decoy ODN drug 
approach results in an adequate immunosuppression with much less toxicity and a 
significantly better outcome with respect to long-term transplant function and survival. We 
believe that the underlying mechanism of action of these nucleic acid-based drugs can spur 
a promising field of research with midterm clinical implementation as a procurable 
perspective. 
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